Regardless of whether you are a PvP player or a PvE player wanting to make an Arc build, this Destiny 2 Sidearm is a must ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

LLNL is developing a new 3D printing technique to create the millions of fuel capsules needed for fusion power plants.

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Physicists have been trying to design fusion reactors, technologies that can generate energy via nuclear fusion processes, ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

Wong, Founder and CEO of HCW Biologics, stated, "In the third quarter 2024, the Company expanded our product portfolio and ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose ...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...

Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...